Summary
In a randomised cross-over trial the combination labetalol/hydrochlorothiazide was compared with the combination of propranolol/hydralazine/hydrochlorothiazide in 34 uncomplicated hypertensive patients, who were not satisfactorily controlled with hydrochlorothiazide 50 mg alone. The elevated diastolic pressure (D.P.) in 27 patients responded satisfactorily to the labetalol schedule and in 28 patients to the propranolol/hydralazine schedule. No difference was found in the rate of decrease of D.P., nor in the disappearance of hypertension — related complaints. Although the duration of the washout between treatments was at least one month, treatment was significantly more efficacious during the second period. Labetalol pre-treatment especially seemed to enhance the effect of subsequent propranolol/hydralazine administration. Side effects due to therapy were rare and were not related to any particular treatment. The median daily dose of labetalol in responders was 600 mg and that of propranolol/hydralazine 120/60 mg (in both therapies hydrochlorothiazide 50 mg was given in addition). Patients showed a slight preference for the labetaol medication. It is concluded that labetalol/hydrochlorothiazide and propranolol/hydralazine/hydrochlorothiazide are equally satisfactory in the treatment of uncomplicated hypertension.
Similar content being viewed by others
References
Beilin LJ, Juel-Jensen BE (1972) Alpha- and beta-adrenergic blockade in hypertension. Lancet 1: 979
Bolli P, Waal-Manning Hendrika J, Wood AJ, Simpson FO (1976) Experience with Labetalol in hypertension. Br J Clin Pharmacol Suppl 3: 765
Brittain RT, Levy GP (1976) A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor blocking drug. Br J Clin Pharmacol Suppl: 681
Dawson A, Johnson BF, Smith IK, Munro-Faure AD (1979) A comparison of the effects of labetalol, bendrofluazide and their combination in hypertension. Br J Clin Pharmacol 8: 149
Farmer JB, Kennedy I, Levy GP, Marshall RJ (1972) Pharmacology of AH 5158; a drug which blocks both alpha- and beta-adrenoceptors. Br J Pharmacol 45: 660
Hansson L, Olander R, Aberg H, Malmcrona R, Westerlund A (1971) Treatment of hypertension with propranolol and hydralaline. Acta Med Scand 190: 531
Kane J, Gregg I (1976) A double blind trial of labetalol. Br J Clin Pharmacol Suppl 3, 737
Majid PA, Meeran MK, Beaim ME, Sharma B, Taylor SH (1974) Alpha- and beta-adrenergic receptor blockage in the treatment of hypertension. Br Heart J 36: 588
Pritchard BNC, Boakes AJ (1976) Labetalol in long-term treatment of hypertension. Br J Clin Pharmacol Suppl 3: 743
Pugsley DJ, Armstrong BK, Nassim MA, Beilin LJ (1976) Controlled comparison of labetalol and propranolol in the management of severe hypertension. Br J Clin Pharmacol Suppl 3: 777
Pugsley DJ, Nassim M, Armstrong BK, Beilin LJ (1979) A controlled trial of labetalol (trandate), propranolol and placebo in the management of mild to moderate hypertension. Br J Clin Pharmacol 7: 63
Richards DA, Woodings EP, Maconochie JG (1977) Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise. Br J Clin Pharmacol 4: 15
Sanders GL, Routledge PA, Rao JG, Gales GM, Davies DM, Rawlins MD (1978) Labetalol, a cross-over double blind controlled trial. Eur J Clin Pharmacol 14: 301
Siitonen L, Jänne J, Keyriläinen O, Koskinen P, Leskinen O, Pitkäjärvi T, Reinikainen M (1974) Hydralazine and beta-adrenergic blockade in the treatment of hypertension. Ann Clin Res 6: 341
Zacest R, Gilmore E, Koch-Weser J (1971) Treatment of essential hypertension by combined vasodilation and adrenergic blockade. Clin Pharmacol Ther 12: 305
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van der Veur, E., ten Berge, B.S., Donker, A.J.M. et al. Comparison of labetalol, propranolol and hydralazine in hypertensive out-patients. Eur J Clin Pharmacol 21, 457–460 (1982). https://doi.org/10.1007/BF00542038
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542038